Amgen quarterly profit tops Street

Amgen Inc reported much better-than-expected 2nd-Q earnings, helped by a rebound in sales of its rheumatoid arthritis drug and a tax benefit, & it raised full-year profit forecast. Amgen, whose shares rose 3%, also announced it has a deal with GlaxoSmithKline under which the British drugmaker will commercialize Amgen's eagerly awaited experimental osteoporosis drug denosumab in Europe and emerging markets. The quarterly results beat analysts' average expectations by 12